In a 49-year-old male with chronic hepatitis C infection, which baseline tests are required before initiating ledipasvir‑sofosbuvir (Harvoni), and is a liver ultrasound or FibroSure serum fibrosis panel preferred for assessing cirrhosis?

Baseline Testing Before Starting Harvoni

Before initiating Harvoni in this 49-year-old hepatitis C positive male, you must test for hepatitis B (HBsAg and anti-HBc), calculate FIB-4 score to assess for cirrhosis, obtain a liver ultrasound within 6 months to exclude hepatocellular carcinoma and subclinical ascites, perform a hepatic function panel with CBC and INR, and conduct medication reconciliation for drug-drug interactions 1, 2.

Required Pre-Treatment Tests

Mandatory Hepatitis B Screening

• HBsAg and anti-HBc must be checked before starting Harvoni due to the FDA black box warning about HBV reactivation, which can cause fulminant hepatitis, hepatic failure, and death 2. This is non-negotiable.

Cirrhosis Assessment via FIB-4 Score

• Calculate FIB-4 score first - this is the recommended initial screening tool per AASLD/IDSA guidelines 1
• A FIB-4 >3.25 indicates presumed cirrhosis and requires additional evaluation
• If cirrhosis is present, calculate Child-Turcotte-Pugh (CTP) score to determine if compensated (CTP A) versus decompensated (CTP B or C), as this affects treatment duration and whether ribavirin is needed 1

Liver Imaging

• Ultrasound of the liver (within the prior 6 months) is specifically recommended to:
  • Exclude hepatocellular carcinoma (HCC)
  • Detect subclinical ascites 1
• This imaging requirement is explicitly stated in the AASLD/IDSA simplified treatment guidelines

Laboratory Panel

• Hepatic function panel (AST, ALT, bilirubin, albumin)
• Complete blood count (CBC) - platelet count <150,000/mm³ suggests cirrhosis
• INR
• Quantitative HCV RNA (baseline viral load)
• HCV genotype if not already known 1

Medication Review

• Comprehensive medication reconciliation including over-the-counter drugs and herbal/dietary supplements
• Assess for drug-drug interactions, particularly P-gp inducers (rifampin, St. John's wort) which are contraindicated 2
• Special attention to amiodarone - coadministration with Harvoni can cause serious symptomatic bradycardia and is not recommended 2

---

FIB-4 vs. FibroSure for Cirrhosis Assessment

FIB-4 score is superior to FibroSure (or ultrasound alone) as the initial assessment tool for cirrhosis in this patient because it is the guideline-recommended first-line screening method, is free to calculate, and has comparable diagnostic accuracy to proprietary serum panels 1.

Why FIB-4 is Preferred Initially

The 2020 AASLD/IDSA guidelines explicitly recommend calculating FIB-4 score as the primary screening tool for cirrhosis assessment 1. This approach is:

• Cost-effective: Uses routine lab values (AST, ALT, platelets, age) already obtained in standard hepatitis C workup
• Guideline-endorsed: Specifically mentioned as the first step in the pretreatment assessment algorithm 1
• Adequate sensitivity: FIB-4 >3.25 has good performance for identifying cirrhosis

FibroSure Performance

FibroSure (and similar proprietary serum panels) have demonstrated:

• Good diagnostic accuracy for detecting moderate-severe fibrosis (AUROC 0.89 for stages 2-4) 3
• High sensitivity (1.00) but lower specificity (0.61) for detecting significant fibrosis 3
• Comparable performance to other serum marker panels like FIBROSpect II 3
• Ability to track fibrosis changes during and after treatment, with scores decreasing in patients achieving sustained virological response 4

However, FibroSure has limitations:

• Proprietary and expensive
• Not specifically recommended in current AASLD/IDSA guidelines for initial assessment 1
• Simple biochemical indices (like FIB-4) had high indeterminate rates (31-40%) at baseline in some studies 3

Ultrasound Limitations for Fibrosis

Standard grayscale ultrasound is inadequate for assessing fibrosis stage and cannot replace the need for fibrosis scoring:

• Sensitivity of only 27.4% for detecting stage II or higher fibrosis 5
• Sensitivity of only 13.6% for detecting stage III or higher fibrosis 5
• No correlation between sonographic patterns and histological fibrosis stage 5
• Ultrasound is required pre-treatment, but specifically to exclude HCC and ascites, not to stage fibrosis 1

Elastography as an Alternative

If FIB-4 suggests cirrhosis (>3.25), the guidelines accept transient elastography (FibroScan) as confirmatory evidence:

• FibroScan stiffness >12.5 kPa indicates cirrhosis 1
• More recent evidence shows elastography combined with serum markers provides better assessment than either alone 6, 7
• However, elastography is not universally available and is not required if FIB-4 and clinical findings are sufficient 1

---

Clinical Algorithm

Step 1: Calculate FIB-4 score using baseline labs

Step 2:

• If FIB-4 ≤3.25: Presumed no cirrhosis → Harvoni 12 weeks
• If FIB-4 >3.25: Presumed cirrhosis → proceed to Step 3

Step 3 (if FIB-4 >3.25): Confirm cirrhosis with one of:

• Transient elastography (>12.5 kPa)
• Clinical evidence (nodular liver/splenomegaly on ultrasound, platelets <150,000)
• Proprietary serum test like FibroSure if available
• Prior liver biopsy showing cirrhosis

Step 4 (if cirrhosis confirmed): Calculate CTP score

• CTP A (compensated): Harvoni 24 weeks
• CTP B or C (decompensated): Harvoni + ribavirin 12 weeks (not eligible for simplified treatment) 1

---

Important Caveats

• Inflammatory activity confounds liver stiffness measurements - active hepatitis can falsely elevate elastography results 8, 9
• FIB-4 cutoffs validated for untreated HCV should not be used post-SVR to assess fibrosis regression 8
• If the patient has end-stage renal disease (eGFR <30), he is not eligible for simplified treatment and needs specialist referral 1
• HIV or active HBV coinfection also excludes him from simplified treatment protocols 1
• The ultrasound must be recent (within 6 months) - if older imaging exists, repeat it 1